Illumina (ILMN)
(Delayed Data from NSDQ)
$149.76 USD
+5.62 (3.90%)
Updated Nov 1, 2024 04:00 PM ET
Pre-Market: $150.77 +1.01 (0.67%) 8:16 AM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$149.76 USD
+5.62 (3.90%)
Updated Nov 1, 2024 04:00 PM ET
Pre-Market: $150.77 +1.01 (0.67%) 8:16 AM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Zacks News
Zai Lab Stock Down, Atopic Dermatitis Candidate Trial Fails
by Zacks Equity Research
Shares of Zai Lab (ZLAB) decline following the failure of a phase IIA study on its pipeline candidate, ZL-3101, for the treatment of atopic dermatitis.
5 Momentum Stocks Worth Investing in via Driehaus Strategy
by Zacks Equity Research
Using the "buy high and sell higher" rule, Richard Herman Driehaus has created an investment approach.
Indexes Close at Record High as Markets Move North: 5 Picks
by Nalak Das
As a result of markets' northbound movement, two major indexes ??? S&P 500 and Nasdaq Composite ??? closed at an all-time high on Aug 24.
Here's Why You Should Invest in Integer (ITGR) Stock Now
by Zacks Equity Research
Integer Holdings (ITGR) gains on strong quarterly performance. The company is likely to gain from the Cardio & Vascular, Neuromodulation and Non-Medical Electrochem markets.
Veeva Systems (VEEV) Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Veeva Systems (VEEV) gains from its flagship Vault platform. Also, expanding margins are an added positive for the company.
AbbVie Posts Positive Data on Elagolix for Uterine Fibroids
by Zacks Equity Research
AbbVie (ABBV) reports positive top-line results from a phase III extension trial on its investigational candidate Elagolix for treating uterine fibroids in women.
Exact Sciences Inks Cologuard Co-Promotion Deal With Pfizer
by Zacks Equity Research
Exact Sciences (EXAS) reaches a co-promotion agreement with Pfizer to commercialize its non-invasive screening test for colorectal cancer, Cologuard. The stock rallies following this news.
Here's Why You Should Invest in Illumina (ILMN) Stock Now
by Zacks Equity Research
Illumina (ILMN) gains on strategic partnerships and international prospects.
Pacira (PCRX) Rides High on Robust Exparel Performance
by Zacks Equity Research
Pacira (PCRX) focuses on improving sales of its flagship product Exparel. The drug's label expansion programs also look encouraging.
Is Illumina (ILMN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ILMN) Outperforming Other Medical Stocks This Year?
Bull Market Set to Become Longest in History: 5 Picks
by Swarup Gupta
The strength of the economy and the success of U.S. tech majors indicates that the rally isn't going to run out of steam.
Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q4
by Zacks Equity Research
Myriad Genetics (MYGN) witnesses strong performances from GeneSight, EndoPredict, Vectra DA and Prolaris tests in Q4.
Alexion's BLA for ALXN1210 Gets Priority Review From FDA
by Zacks Equity Research
The FDA grants priority review to Alexion's (ALXN) BLA for its C5 complement inhibitor ALXN1210 with respect to the treatment of patients with paroxysmal nocturnal hemoglobinuria.
Medtronic (MDT) Q1 Earnings Beat on Growth in All Lines
by Zacks Equity Research
All major business groups of Medtronic (MDT) contribute to solid top-line growth at CER, which highlighted sustainability across groups and regions.
Roche's Lung Cancer Drug Alecensa Gets Approval in China
by Zacks Equity Research
The China National Drug Administration approves Roche's (RHHBY) cancer drug Alecensa as a monotherapy for first-line treatment of advanced non-small cell lung cancer.
Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?
by Zacks Equity Research
Sector ETF report for ARKG
Zacks.com highlights: Illumina, Vertex Pharmaceuticals, Surmodics and McDermott International
by Zacks Equity Research
Zacks.com highlights: Illumina, Vertex Pharmaceuticals, Surmodics and McDermott International
4 Winning Stocks With Solid Efficiency Level
by Tirthankar Chakraborty
A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.
Evoke Pharma (EVOK) Announces FDA Acceptance of Gimoti NDA
by Zacks Equity Research
The FDA accepts Evoke Pharma's (EVOK) regulatory application seeking approval of its pipeline candidate, Gimoti, for treating diabetic gastroparesis. Shares up.
Accuray (ARAY) Earnings Beat in Q4, Gross Orders Rise Y/Y
by Zacks Equity Research
Accuray's (ARAY) flagship Radixact System drives Q4 results; overseas gains raise hope.
Inovio Pharmaceuticals Initiates Dosing in HIV Vaccine Study
by Zacks Equity Research
Inovio Pharmaceuticals (INO) doses the first patient in a phase I/II study, which will evaluate its HIV vaccine Pennvax-GP's ability to bring about remission of HIV.
Can Illumina (ILMN) Stock Continue to Grow Earnings?
by Zacks Equity Research
Illumina (ILMN) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.
Ligand (LGND) Proposes to Buy U.K.'s Drug Discovery Biotech
by Zacks Equity Research
Ligand (LGND) makes an offer to acquire U.K.-based drug discovery biotech Vernalis to drive the same platform in its portfolio.
Corcept (CORT) Earnings and Revenues Miss Estimates in Q2
by Zacks Equity Research
Corcept's (CORT) earnings and revenues lag estimates in Q2. Meanwhile, the company posts positive interim data from phase I/II study on its pipeline candidate relacorilant.
Puma Biotech (PBYI) Q2 Loss Narrows, Nerlynx Drives Sales
by Zacks Equity Research
Puma Biotech (PBYI) posts narrower-than-estimated loss in Q2. Also, rapid growth of its only marketed drug, Nerlynx, boosts sales.